Published in Medical Letter on the CDC and FDA, November 6th, 2005
"Securing this level of a competitive NIH award validates our anthrax vaccine approach and allows us to quickly move forward in our preclinical development," said Dr. Charles Richardson, LigoCyte senior VP of research and development.
LigoCyte's vaccine programs, aimed against potential agents of biowarfare, continue to be funded by the U.S. Department of Defense (DOD) through appropriations supported by Senator Conrad Burns (R-MT).
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA